These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

81 related articles for article (PubMed ID: 12722313)

  • 1. [Anti-tuberculosis drugs].
    Doi N
    Nihon Rinsho; 2003 Feb; 61 Suppl 2():762-7. PubMed ID: 12722313
    [No Abstract]   [Full Text] [Related]  

  • 2. [Prospects for development of new antituberculous drugs].
    Tomioka H
    Kekkaku; 2002 Aug; 77(8):573-84. PubMed ID: 12235850
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A new TB drug by 2010--or sooner?
    Crabb C
    Bull World Health Organ; 2002; 80(6):518-9. PubMed ID: 12132015
    [No Abstract]   [Full Text] [Related]  

  • 4. Substituted 4-methylquinolines as a new class of anti-tuberculosis agents.
    Jain R; Vaitilingam B; Nayyar A; Palde PB
    Bioorg Med Chem Lett; 2003 Mar; 13(6):1051-4. PubMed ID: 12643909
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mechanisms of drug resistance in Mycobacterium tuberculosis: update 2015.
    Zhang Y; Yew WW
    Int J Tuberc Lung Dis; 2015 Nov; 19(11):1276-89. PubMed ID: 26467578
    [TBL] [Abstract][Full Text] [Related]  

  • 6. New drugs against tuberculosis: problems, progress, and evaluation of agents in clinical development.
    van den Boogaard J; Kibiki GS; Kisanga ER; Boeree MJ; Aarnoutse RE
    Antimicrob Agents Chemother; 2009 Mar; 53(3):849-62. PubMed ID: 19075046
    [No Abstract]   [Full Text] [Related]  

  • 7. Delamanid, Bedaquiline, and Linezolid Minimum Inhibitory Concentration Distributions and Resistance-related Gene Mutations in Multidrug-resistant and Extensively Drug-resistant Tuberculosis in Korea.
    Yang JS; Kim KJ; Choi H; Lee SH
    Ann Lab Med; 2018 Nov; 38(6):563-568. PubMed ID: 30027700
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rifamycins: do not throw the baby out with the bathwater. Is rifampicin still an effective anti-tuberculosis drug?
    Brucoli F; D McHugh T
    Future Med Chem; 2021 Dec; 13(24):2129-2131. PubMed ID: 34643442
    [No Abstract]   [Full Text] [Related]  

  • 9. Tuberculosis drug development: progress, challenges, and the road ahead.
    Ginsberg AM
    Tuberculosis (Edinb); 2010 May; 90(3):162-7. PubMed ID: 20382086
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prospects for new antitubercular drugs.
    Duncan K; Barry CE
    Curr Opin Microbiol; 2004 Oct; 7(5):460-5. PubMed ID: 15451500
    [TBL] [Abstract][Full Text] [Related]  

  • 11. NIAID researchers make key discovery in development of TB drug candidate.
    J Investig Med; 2006 Mar; 54(2):53-4. PubMed ID: 16532548
    [No Abstract]   [Full Text] [Related]  

  • 12. [In vitro activities of rifabutine and rifampicin against various mycobacteria, especially Mycobacterium tuberculosis and Mycobacterium avium complex].
    Saito H; Sato K; Tomioka H
    Kekkaku; 1988 Mar; 63(3):167-72. PubMed ID: 2836649
    [No Abstract]   [Full Text] [Related]  

  • 13. [Progress in the study of drug susceptibility testing of Mycobacterium tuberculosis].
    Zhang YY; Wan KL
    Zhonghua Liu Xing Bing Xue Za Zhi; 2004 Dec; 25(12):1074-7. PubMed ID: 15769370
    [No Abstract]   [Full Text] [Related]  

  • 14. [Anti-tuberculosis drugs].
    Doi N
    Nihon Rinsho; 2007 Feb; 65 Suppl 2 Pt. 1():367-74. PubMed ID: 17455647
    [No Abstract]   [Full Text] [Related]  

  • 15. Tackling Drug-Resistant Tuberculosis: Current Trends and Approaches.
    Tandon R; Nath M
    Mini Rev Med Chem; 2017; 17(6):549-570. PubMed ID: 27280980
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antimycobacterial activity of linezolid against multidrug-resistant and extensively drug-resistant strains of Mycobacterium tuberculosis in Iran.
    Kazemian H; Haeili M; Kardan Yamchi J; Rezaei F; Gizaw Feyisa S; Zahednamazi F; Mohajeri P; Zaker Bostanabd S; Hashemi Shahraki A; Imani Fooladi AA; Feizabadi MM
    Int J Antimicrob Agents; 2015 Jun; 45(6):668-70. PubMed ID: 25795315
    [No Abstract]   [Full Text] [Related]  

  • 17. Re: Review article titled, "Rifamycins - Obstacles and opportunities" by Paul A. Aristoff, George A. Garcia, Paul D. Kirchhoff, H.D. Hollis Showalter. Tuberculosis 2010; 90(2):94-118.
    Sayada C
    Tuberculosis (Edinb); 2010 Sep; 90(5):326; author reply 326-7. PubMed ID: 20691638
    [No Abstract]   [Full Text] [Related]  

  • 18. Mechanisms of resistance to delamanid, a drug for Mycobacterium tuberculosis.
    Fujiwara M; Kawasaki M; Hariguchi N; Liu Y; Matsumoto M
    Tuberculosis (Edinb); 2018 Jan; 108():186-194. PubMed ID: 29523322
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prospects for development of new antimycobacterial drugs, with special reference to a new benzoxazinorifamycin, KRM-1648.
    Tomioka H
    Arch Immunol Ther Exp (Warsz); 2000; 48(3):183-8. PubMed ID: 10912623
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Drugs for tuberculosis.
    Treat Guidel Med Lett; 2004 Dec; 2(28):83-8. PubMed ID: 15557876
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.